ANDA 88936, held by Abraxis Pharmaceuticals. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 88936 (Methotrexate Sodium), held by Abraxis Pharmaceuticals, was not approved, with 1 approved supplement and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 50MG BASE/VIAL · injectable;injection | Methotrexate Sodium | Discontinued |
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 27, 1987 | Supplement 1Manufacturing | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters